The incidence and prevalence of congestive heart failure are actually increasing worldwide, especially inWestern countries. In Europe and the United States, congestive heart failure represents a disabling clinical disease, accountable for increased hospitalization and health care costs. European guidelines have underlined the importance of pharmacological treatment to improve both patients’ outcomes and quality of life. The latest clinical trials to evaluate ivabradine’s efficacy have underlined its usefulness as a stand-alone medication and in combination with conventional congestive heart failure therapy, including in chronic kidney disease patients.
|Titolo:||Ivabradine, heart failure and chronic kidney disease|
BELLASI, ANTONIO (Secondo)
|Parole Chiave:||Beta-blockers; Heart failure; Ivabradine; Ventricular remodeling|
|Settore Scientifico Disciplinare:||Settore MED/14 - Nefrologia|
|Data di pubblicazione:||gen-2016|
|Digital Object Identifier (DOI):||10.5301/poc.5000190|
|Appare nelle tipologie:||01 - Articolo su periodico|